Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer

Baselga et al. ASCO Abstract LBA1006.

Key clinical point: The PI3K inhibitor taselisib added to fulvestrant offered only modest benefit and significant toxicities in patients with advanced ER+/HER2- breast cancer.

Major finding: The combination of taselisib/fulvestrant extend median progression-free survival by two months.

Study details: Phase 3 randomized trial in 516 women with locally advanced or metastatic ER+/HER2- breast cancer.

Disclosures: The study was funded by F. Hoffman La-Roche. Dr. Baselga had disclosures related to GRAIL, Lilly, and Novartis, Infinity Pharmaceuticals, and Varian Medical Systems, PMV Pharma, and Juno Therapeutics. Dr. Burstein disclosed institutional research funding and speaker’s bureau activities for Novartis. Dr. Ma reported no relevant disclosures.

Source: Baselga et al. ASCO Abstract LBA1006.

Read the article.

Citation:

Baselga et al. ASCO Abstract LBA1006.